MammaPrint Index as a predictive biomarker
Genomic signatures have shown promise in predicting the pathological complete response and treatment benefits of neoadjuvant chemotherapy in early breast cancer more accurately than traditional subtyping methods. The 70-gene MammaPrint test, specifically designed to assess the risk of distant metastasis, categorises patients as having either a Low or High Risk profile.
In the ISPY2 trial, further refinement of the MammaPrint High Risk category into High 1 and High 2 subgroups improved the ability to predict chemosensitivity. Building upon these findings, Dr Peter Beitsch from the Dallas Surgical Group presented a poster at the conference. His evaluation focused on assessing the utility of the High 1/High 2 risk classification as a biomarker for chemosensitivity and 5-year distant-metastasis-free survival in patients participating in the Neoadjuvant Breast Registry Symphony Trial. The study aimed to determine the effectiveness of this biomarker in guiding treatment decisions and predicting long-term outcomes for patients undergoing neoadjuvant therapy for breast cancer.
With the educational support of:
